董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| William Wexler | 男 | Director | 66 | 3.60万美元 | 0.02 | 2026-03-12 |
| Sanjeev Luther | 男 | President, Chief Executive Officer and Director | 64 | 88.88万美元 | 0.50 | 2026-03-12 |
| Peter Cicala | 男 | Director | 64 | 1.49万美元 | 0.03 | 2026-03-12 |
| Elena Ratner | 女 | Director | 49 | 3.72万美元 | 0.02 | 2026-03-12 |
| James Bristol | 男 | Director and Chairman of the Board | 79 | 2.08万美元 | 0.04 | 2026-03-12 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Sandra Gurrola | 女 | Senior Vice President, Finance | 59 | 32.94万美元 | 0.02 | 2026-03-12 |
| Sanjeev Luther | 男 | President, Chief Executive Officer and Director | 64 | 88.88万美元 | 0.50 | 2026-03-12 |
董事简历
中英对照 | 中文 | 英文- William Wexler
-
William Wexler自2022年6月起担任Eterna Therapeutics Inc.董事会成员。在加入Eterna Therapeutics Inc.董事会之前，Wexler先生参与了150多个个人项目，担任过各种职务，包括董事长、首席执行官、首席重组官和其他指定的高级职责。韦克斯勒先生自2012年起担任管理咨询公司WEXLER Consulting LLC的管理成员。2012年至2019年，他担任过多个职务，包括担任Upstate New York Power Products，Inc.的董事会主席、临时首席执行官、首席执行官、唯一董事和股东代表。Upstate New York Power Products，Inc.是一家控股公司，在纽约州北部拥有并运营发电厂。2012年至2013年，韦克斯勒先生担任VMR Electronics，LLC的首席重组官，该公司是一家为电子互连行业生产电缆组装产品的制造商。在此之前，他曾于2006年至2011年在转型咨询公司步步高有限公司担任董事总经理和国家金融业务主管。韦克斯勒先生曾于2002年至2005年在Huron Consulting Group，LLC担任集团企业重组董事总经理。此前，他曾于2000年至2002年在精品投资银行公司Berenson Minella & Co.担任董事总经理。1986年至2000年间，他在法国巴黎银行担任高级董事，在那里他成立并领导了巴黎银行的房地产投资部门Paribas Properties，Inc.，并担任当时新成立的美国资产重组集团的首席执行官。韦克斯勒的职业生涯始于1981年，他在仲量联行（Jones Lang Wootton，现为仲量联行）从事商业租赁经纪、资产管理和投资销售工作，直到1986年。他在约翰·霍普金斯大学获得政治学学士学位。韦克斯勒先生在Eterna Therapeutics Inc.董事会任职的资格包括他在投资和高级管理职位方面的经验，以及他的商业培训和教育。
William Wexler has served as a member of board of directors since June 2022. Prior to joining board of directors, Mr. xler worked on over 150 individual projects, serving in vario capacities including as Chairman, Chief Executive Officer, Chief Restructuring Officer and other designated roles of senior responsibility. Mr. xler has served as the Managing Member of XLER Consulting LLC, a management consulting firm, since 2012. From 2012 to 2019, he served in vario roles, including as Chairman of the Board, interim Chief Executive Officer, Chief Executive Officer and sole director and stockholder representative of Upstate New York Por Products, Inc., a holding company that owned and operated por plants throughout upstate New York. From 2012 to 2013, Mr. xler served as Chief Restructuring Officer of VMR Electronics, LLC, a manufacturer of cable assembly products for the electronics interconnect indtry. Prior to that, he served as a Managing Director and national finance practice lead at BBK, Ltd., a turn around advisory firm, from 2006 to 2011. Mr. xler served as group Managing Director of corporate restructuring at Huron Consulting Group, LLC from 2002 to 2005. Previoly, he was a Managing Director at Berenson Minella & Co., a boutique investment banking firm, from 2000 to 2002. Beten 1986 and 2000 he served as a Senior Director at BNP Paribas, where he established and led Paribas Properties, Inc., a real estate investment arm of the bank, and also where he was a lead officer of the then newly created U.S. asset workout group. Mr. xler started his professional career in 1981 in commercial lease brokerage, asset management and investment sales at Jones Lang Wootton (now Jones Lang LaSalle) where he worked until 1986. He earned a B.A. in Political Science from Johns Hopkins University. - William Wexler自2022年6月起担任Eterna Therapeutics Inc.董事会成员。在加入Eterna Therapeutics Inc.董事会之前，Wexler先生参与了150多个个人项目，担任过各种职务，包括董事长、首席执行官、首席重组官和其他指定的高级职责。韦克斯勒先生自2012年起担任管理咨询公司WEXLER Consulting LLC的管理成员。2012年至2019年，他担任过多个职务，包括担任Upstate New York Power Products，Inc.的董事会主席、临时首席执行官、首席执行官、唯一董事和股东代表。Upstate New York Power Products，Inc.是一家控股公司，在纽约州北部拥有并运营发电厂。2012年至2013年，韦克斯勒先生担任VMR Electronics，LLC的首席重组官，该公司是一家为电子互连行业生产电缆组装产品的制造商。在此之前，他曾于2006年至2011年在转型咨询公司步步高有限公司担任董事总经理和国家金融业务主管。韦克斯勒先生曾于2002年至2005年在Huron Consulting Group，LLC担任集团企业重组董事总经理。此前，他曾于2000年至2002年在精品投资银行公司Berenson Minella & Co.担任董事总经理。1986年至2000年间，他在法国巴黎银行担任高级董事，在那里他成立并领导了巴黎银行的房地产投资部门Paribas Properties，Inc.，并担任当时新成立的美国资产重组集团的首席执行官。韦克斯勒的职业生涯始于1981年，他在仲量联行（Jones Lang Wootton，现为仲量联行）从事商业租赁经纪、资产管理和投资销售工作，直到1986年。他在约翰·霍普金斯大学获得政治学学士学位。韦克斯勒先生在Eterna Therapeutics Inc.董事会任职的资格包括他在投资和高级管理职位方面的经验，以及他的商业培训和教育。
- William Wexler has served as a member of board of directors since June 2022. Prior to joining board of directors, Mr. xler worked on over 150 individual projects, serving in vario capacities including as Chairman, Chief Executive Officer, Chief Restructuring Officer and other designated roles of senior responsibility. Mr. xler has served as the Managing Member of XLER Consulting LLC, a management consulting firm, since 2012. From 2012 to 2019, he served in vario roles, including as Chairman of the Board, interim Chief Executive Officer, Chief Executive Officer and sole director and stockholder representative of Upstate New York Por Products, Inc., a holding company that owned and operated por plants throughout upstate New York. From 2012 to 2013, Mr. xler served as Chief Restructuring Officer of VMR Electronics, LLC, a manufacturer of cable assembly products for the electronics interconnect indtry. Prior to that, he served as a Managing Director and national finance practice lead at BBK, Ltd., a turn around advisory firm, from 2006 to 2011. Mr. xler served as group Managing Director of corporate restructuring at Huron Consulting Group, LLC from 2002 to 2005. Previoly, he was a Managing Director at Berenson Minella & Co., a boutique investment banking firm, from 2000 to 2002. Beten 1986 and 2000 he served as a Senior Director at BNP Paribas, where he established and led Paribas Properties, Inc., a real estate investment arm of the bank, and also where he was a lead officer of the then newly created U.S. asset workout group. Mr. xler started his professional career in 1981 in commercial lease brokerage, asset management and investment sales at Jones Lang Wootton (now Jones Lang LaSalle) where he worked until 1986. He earned a B.A. in Political Science from Johns Hopkins University.
- Sanjeev Luther
-
Sanjeev Luther，自2024年1月1日起担任总裁、首席执行官和Eterna Therapeutics Inc.董事会成员。在此之前，Luther先生于2017年11月至2023年12月担任Cornerstone Pharmaceuticals的总裁、首席执行官和董事会成员，并于2014年12月至2017年11月担任其首席运营官和首席商务官。在此之前，路德先生曾在百时美施贵宝、诺华、博士伦和通用电气医疗集团担任过各种领导职务。路德先生拥有纽约州立大学布法罗分校市场营销MBA学位和市场营销和工商管理学士学位。
Sanjeev Luther has served as President, Chief Executive Officer and as a member of board of directors since January 2024. Prior to that, Mr. Luther served as President, Chief Executive Officer and a board member of Cornerstone Pharmaceuticals from November 2017 to December 2023 and as its Chief Operations Officer and Chief Biness Officer from December 2014 to November 2017. Prior to that, Mr. Luther served in vario leadership roles at Bristol Myers Squibb, Novartis, Bach and Lomb and GE Healthcare. Mr. Luther holds an MBA in Marketing and a B.S. in Marketing and Biness Administration from the State University of New York at Buffalo. - Sanjeev Luther，自2024年1月1日起担任总裁、首席执行官和Eterna Therapeutics Inc.董事会成员。在此之前，Luther先生于2017年11月至2023年12月担任Cornerstone Pharmaceuticals的总裁、首席执行官和董事会成员，并于2014年12月至2017年11月担任其首席运营官和首席商务官。在此之前，路德先生曾在百时美施贵宝、诺华、博士伦和通用电气医疗集团担任过各种领导职务。路德先生拥有纽约州立大学布法罗分校市场营销MBA学位和市场营销和工商管理学士学位。
- Sanjeev Luther has served as President, Chief Executive Officer and as a member of board of directors since January 2024. Prior to that, Mr. Luther served as President, Chief Executive Officer and a board member of Cornerstone Pharmaceuticals from November 2017 to December 2023 and as its Chief Operations Officer and Chief Biness Officer from December 2014 to November 2017. Prior to that, Mr. Luther served in vario leadership roles at Bristol Myers Squibb, Novartis, Bach and Lomb and GE Healthcare. Mr. Luther holds an MBA in Marketing and a B.S. in Marketing and Biness Administration from the State University of New York at Buffalo.
- Peter Cicala
-
Peter Cicala，自2024年2月起担任Eterna Therapeutics Inc.董事会成员。Cicala先生目前担任一家私营生物技术公司的总法律顾问，自2021年3月以来，他一直担任该公司的总法律顾问。2019年11月，他与人共同创立了生物技术公司Pretzel Therapeutics，Inc.，至今仍担任执行顾问。2020年3月至2021年3月，Cicala先生担任Intercept制药，Inc.的首席知识产权法律顾问，并于2014年3月至2019年11月担任新基医药公司的首席专利法律顾问，这两家公司均为上市生物制药公司。Cicala先生拥有超过25年的法律从业经验，同时也拥有超过10年的药物化学家经验。他在Fairleigh Dickinson大学获得化学学士学位，在Seton Hall大学法学院获得法学博士学位。
Peter Cicala has served as a member of board of directors since February 2024. Mr. Cicala currently serves as General Counsel for a private biotechnology company, where he has been since March of 2021. In November of 2019, he co founded Pretzel Therapeutics, Inc., a biotechnology company, and still serves as an executive advisor. From March 2020 until March 2021, Mr. Cicala served as Chief Intellectual Property Counsel for Intercept Pharmaceuticals, Inc. and from March 2014 until November 2019, he served as Chief Patent Counsel for Celgene Corporation, both publicly traded biopharmaceutical companies. Mr. Cicala has practiced law for over 25 years, and also has over 10 years of experience as a medicinal chemist. He received his B.S. in chemistry from Fairleigh Dickinson University and a J.D. from Seton Hall University School of Law. - Peter Cicala，自2024年2月起担任Eterna Therapeutics Inc.董事会成员。Cicala先生目前担任一家私营生物技术公司的总法律顾问，自2021年3月以来，他一直担任该公司的总法律顾问。2019年11月，他与人共同创立了生物技术公司Pretzel Therapeutics，Inc.，至今仍担任执行顾问。2020年3月至2021年3月，Cicala先生担任Intercept制药，Inc.的首席知识产权法律顾问，并于2014年3月至2019年11月担任新基医药公司的首席专利法律顾问，这两家公司均为上市生物制药公司。Cicala先生拥有超过25年的法律从业经验，同时也拥有超过10年的药物化学家经验。他在Fairleigh Dickinson大学获得化学学士学位，在Seton Hall大学法学院获得法学博士学位。
- Peter Cicala has served as a member of board of directors since February 2024. Mr. Cicala currently serves as General Counsel for a private biotechnology company, where he has been since March of 2021. In November of 2019, he co founded Pretzel Therapeutics, Inc., a biotechnology company, and still serves as an executive advisor. From March 2020 until March 2021, Mr. Cicala served as Chief Intellectual Property Counsel for Intercept Pharmaceuticals, Inc. and from March 2014 until November 2019, he served as Chief Patent Counsel for Celgene Corporation, both publicly traded biopharmaceutical companies. Mr. Cicala has practiced law for over 25 years, and also has over 10 years of experience as a medicinal chemist. He received his B.S. in chemistry from Fairleigh Dickinson University and a J.D. from Seton Hall University School of Law.
- Elena Ratner
-
Elena Ratner自2025年1月起担任董事会成员。自2019年7月以来，Ratner博士一直担任耶鲁大学医学院妇产科和生殖科学系的教授，同时还担任Discovery to Cure Early Ovarian Detection Program的主任。拉特纳博士的临床研究重点是新的卵巢癌靶向药物，以及逆转卵巢癌和子宫癌的化疗耐药性。她在哥伦比亚大学巴纳德学院获得医学预科学士学位，在耶鲁大学获得MBA学位，在布法罗大学获得医学博士学位。
Elena Ratner has served as a member of board of directors since January 2025. Since July 2019, Dr. Ratner has been serving as a professor in the Department of Obstetrics, Gynecology and Reproductive Sciences at Yale University School of Medicine and also serves as the director of the Discovery to Cure Early Ovarian Detection program. Dr. Ratner's clinical research has focused on new targeted drugs for ovarian cancer and on reversing chemotherapy resistance in ovarian and uterine cancers. She received her B.S. in premedical studies from Barnard College at Columbia University, her MBA at Yale University and her M.D. from the University of Buffalo. - Elena Ratner自2025年1月起担任董事会成员。自2019年7月以来，Ratner博士一直担任耶鲁大学医学院妇产科和生殖科学系的教授，同时还担任Discovery to Cure Early Ovarian Detection Program的主任。拉特纳博士的临床研究重点是新的卵巢癌靶向药物，以及逆转卵巢癌和子宫癌的化疗耐药性。她在哥伦比亚大学巴纳德学院获得医学预科学士学位，在耶鲁大学获得MBA学位，在布法罗大学获得医学博士学位。
- Elena Ratner has served as a member of board of directors since January 2025. Since July 2019, Dr. Ratner has been serving as a professor in the Department of Obstetrics, Gynecology and Reproductive Sciences at Yale University School of Medicine and also serves as the director of the Discovery to Cure Early Ovarian Detection program. Dr. Ratner's clinical research has focused on new targeted drugs for ovarian cancer and on reversing chemotherapy resistance in ovarian and uterine cancers. She received her B.S. in premedical studies from Barnard College at Columbia University, her MBA at Yale University and her M.D. from the University of Buffalo.
- James Bristol
-
James Bristol，博士，2014年2月28日加入Ignyta董事会。他在Schering-Plough, Parke-Davis and Pfizer工作了33年，任药物研究和临床前开发领域不同高级研发职位。2003年至2007年退休，他任Pfizer Global Research & Development全球药物开发副总裁。2007年起他是Deciphera Pharmaceuticals, LLC管理委员会联合主席，任管理成员。2011年起他在Mnemosyne Pharmaceuticals, Inc任董事。2009年，他加入Frazier Healthcare Ventures，任高级顾问。他拥有100多篇论文、文摘和专利。他在University of Michigan N.I.H.Postdoctoral Fellow以及at The Squibb Institute for Medical Research做博士后研究。他拥有University of New Hampshire有机化学博士学位，Bates College化学专业学士学位。
James Bristol has served as a member of board of directors since October 2023. Dr. Bristol worked for 40 years in drug discovery, research and preclinical development at Schering Plough Corporation, Parke Davis, and Pfizer Inc. ("Pfizer"), serving in vario senior research and development roles. From 2003 until his retirement in 2007, Dr. Bristol served as Senior Vice President of Worldwide Drug Discovery Research at Pfizer Global Research & Development, where he oversaw 3,000 scientists at seven Pfizer sites as they produced an indtry leading number of drug development candidates in 11 therapeutic areas. In 2009, Dr. Bristol joined Frazier Life Sciences as a Senior Advisor. From Augt 2007 until December 2024, Dr. Bristol has served as a member of the board of directors of Deciphera Pharmaceuticals, and since 2018 he has served as a member of the board of directors of Erasca, Inc., both of which are publicly traded life science companies. He is currently a member of the board of directors of Genuiti. Dr. Bristol also served on the board of directors of Ignyta from 2014 until its acquisition by Roche in 2018, and served on the board of directors of SUDO Biosciences, Inc. from June 2021 until December 2023, and of Cadent Therapeutics, Inc. from 2011 until 2020. Dr. Bristol is the author of over 100 publications, abstracts and patents, and he conducted postdoctoral research at the University of Michigan (NIH Postdoctoral Fellow) and at The Squibb Institute for Medical Research. Dr. Bristol holds a Ph.D. in organic chemistry from the University of New Hampshire and a B.S. in Chemistry from Bates College. - James Bristol，博士，2014年2月28日加入Ignyta董事会。他在Schering-Plough, Parke-Davis and Pfizer工作了33年，任药物研究和临床前开发领域不同高级研发职位。2003年至2007年退休，他任Pfizer Global Research & Development全球药物开发副总裁。2007年起他是Deciphera Pharmaceuticals, LLC管理委员会联合主席，任管理成员。2011年起他在Mnemosyne Pharmaceuticals, Inc任董事。2009年，他加入Frazier Healthcare Ventures，任高级顾问。他拥有100多篇论文、文摘和专利。他在University of Michigan N.I.H.Postdoctoral Fellow以及at The Squibb Institute for Medical Research做博士后研究。他拥有University of New Hampshire有机化学博士学位，Bates College化学专业学士学位。
- James Bristol has served as a member of board of directors since October 2023. Dr. Bristol worked for 40 years in drug discovery, research and preclinical development at Schering Plough Corporation, Parke Davis, and Pfizer Inc. ("Pfizer"), serving in vario senior research and development roles. From 2003 until his retirement in 2007, Dr. Bristol served as Senior Vice President of Worldwide Drug Discovery Research at Pfizer Global Research & Development, where he oversaw 3,000 scientists at seven Pfizer sites as they produced an indtry leading number of drug development candidates in 11 therapeutic areas. In 2009, Dr. Bristol joined Frazier Life Sciences as a Senior Advisor. From Augt 2007 until December 2024, Dr. Bristol has served as a member of the board of directors of Deciphera Pharmaceuticals, and since 2018 he has served as a member of the board of directors of Erasca, Inc., both of which are publicly traded life science companies. He is currently a member of the board of directors of Genuiti. Dr. Bristol also served on the board of directors of Ignyta from 2014 until its acquisition by Roche in 2018, and served on the board of directors of SUDO Biosciences, Inc. from June 2021 until December 2023, and of Cadent Therapeutics, Inc. from 2011 until 2020. Dr. Bristol is the author of over 100 publications, abstracts and patents, and he conducted postdoctoral research at the University of Michigan (NIH Postdoctoral Fellow) and at The Squibb Institute for Medical Research. Dr. Bristol holds a Ph.D. in organic chemistry from the University of New Hampshire and a B.S. in Chemistry from Bates College.
高管简历
中英对照 | 中文 | 英文- Sandra Gurrola
Sandra Gurrola，曾担任Eterna Therapeutics公司。自2023年5月起担任财务高级副总裁。从2021年6月到2023年5月担任财务副总裁。在此之前，她曾担任eGames.com Holdings， LLC的高级副总裁（2021年3月至2021年6月），以及Eterna Therapeutics Inc.的顾问。Gurrola女士于2019年9月至2021年3月担任NTN Buzztime， Inc.的高级财务副总裁，并于2014年至2019年担任财务副总裁。从2009年到2014年，她曾担任NTN Buzztime， Inc.的各种领导会计职位，包括财务总监、会计总监、财务报告和合规总监。此前，她是Metabasis Therapeutics， Inc.（生物技术公司）的财务报告高级经理。她持有圣地亚哥州立大学（San Diego State University）的英语学士学位。
Sandra Gurrola has served as Senior Vice President of Finance since May 2023 and served as Vice President of Finance from June 2021 until May 2023. Prior to that, she served as the Senior Vice President of eGames.com Holdings, LLC from March 2021 to June 2021 and as a consultant to . Ms. Gurrola served as Senior Vice President of Finance to NTN Buzztime, Inc. from September 2019 to March 2021 and its Vice President of Finance from 2014 until 2019. From 2009 to 2014, Ms. Gurrola served NTN Buzztime, Inc. in vario leadership accounting roles, including Controller, Director of Accounting, and Director of Financial Reporting and Compliance. Previoly, she was a senior manager of financial reporting for Metabasis Therapeutics, Inc., a biotechnology company. Ms. Gurrola received a B.A. in English from San Diego State University.- Sandra Gurrola，曾担任Eterna Therapeutics公司。自2023年5月起担任财务高级副总裁。从2021年6月到2023年5月担任财务副总裁。在此之前，她曾担任eGames.com Holdings， LLC的高级副总裁（2021年3月至2021年6月），以及Eterna Therapeutics Inc.的顾问。Gurrola女士于2019年9月至2021年3月担任NTN Buzztime， Inc.的高级财务副总裁，并于2014年至2019年担任财务副总裁。从2009年到2014年，她曾担任NTN Buzztime， Inc.的各种领导会计职位，包括财务总监、会计总监、财务报告和合规总监。此前，她是Metabasis Therapeutics， Inc.（生物技术公司）的财务报告高级经理。她持有圣地亚哥州立大学（San Diego State University）的英语学士学位。
- Sandra Gurrola has served as Senior Vice President of Finance since May 2023 and served as Vice President of Finance from June 2021 until May 2023. Prior to that, she served as the Senior Vice President of eGames.com Holdings, LLC from March 2021 to June 2021 and as a consultant to . Ms. Gurrola served as Senior Vice President of Finance to NTN Buzztime, Inc. from September 2019 to March 2021 and its Vice President of Finance from 2014 until 2019. From 2009 to 2014, Ms. Gurrola served NTN Buzztime, Inc. in vario leadership accounting roles, including Controller, Director of Accounting, and Director of Financial Reporting and Compliance. Previoly, she was a senior manager of financial reporting for Metabasis Therapeutics, Inc., a biotechnology company. Ms. Gurrola received a B.A. in English from San Diego State University.
- Sanjeev Luther
Sanjeev Luther，自2024年1月1日起担任总裁、首席执行官和Eterna Therapeutics Inc.董事会成员。在此之前，Luther先生于2017年11月至2023年12月担任Cornerstone Pharmaceuticals的总裁、首席执行官和董事会成员，并于2014年12月至2017年11月担任其首席运营官和首席商务官。在此之前，路德先生曾在百时美施贵宝、诺华、博士伦和通用电气医疗集团担任过各种领导职务。路德先生拥有纽约州立大学布法罗分校市场营销MBA学位和市场营销和工商管理学士学位。
Sanjeev Luther has served as President, Chief Executive Officer and as a member of board of directors since January 2024. Prior to that, Mr. Luther served as President, Chief Executive Officer and a board member of Cornerstone Pharmaceuticals from November 2017 to December 2023 and as its Chief Operations Officer and Chief Biness Officer from December 2014 to November 2017. Prior to that, Mr. Luther served in vario leadership roles at Bristol Myers Squibb, Novartis, Bach and Lomb and GE Healthcare. Mr. Luther holds an MBA in Marketing and a B.S. in Marketing and Biness Administration from the State University of New York at Buffalo.- Sanjeev Luther，自2024年1月1日起担任总裁、首席执行官和Eterna Therapeutics Inc.董事会成员。在此之前，Luther先生于2017年11月至2023年12月担任Cornerstone Pharmaceuticals的总裁、首席执行官和董事会成员，并于2014年12月至2017年11月担任其首席运营官和首席商务官。在此之前，路德先生曾在百时美施贵宝、诺华、博士伦和通用电气医疗集团担任过各种领导职务。路德先生拥有纽约州立大学布法罗分校市场营销MBA学位和市场营销和工商管理学士学位。
- Sanjeev Luther has served as President, Chief Executive Officer and as a member of board of directors since January 2024. Prior to that, Mr. Luther served as President, Chief Executive Officer and a board member of Cornerstone Pharmaceuticals from November 2017 to December 2023 and as its Chief Operations Officer and Chief Biness Officer from December 2014 to November 2017. Prior to that, Mr. Luther served in vario leadership roles at Bristol Myers Squibb, Novartis, Bach and Lomb and GE Healthcare. Mr. Luther holds an MBA in Marketing and a B.S. in Marketing and Biness Administration from the State University of New York at Buffalo.